MedTrace Logo

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

NCT07217496 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-03-17

No results posted yet for this study

Summary

This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).

Conditions

Interventions

DRUG

Nogapendekin Alfa Inbakicept (N803)

Given subcutaneously (SC)

DRUG

Enfortumab Vedotin (EV)

Given intravenously (IV)

DRUG

Pembrolizumab

Given intravenously (IV)

PROCEDURE

Research Biospecimen Collection

Undergo blood collection for research purposes

PROCEDURE

Radiographic Imaging

Undergo radiographic imaging for disease assessment

PROCEDURE

Tumor Biopsy

Undergo tumor biopsy

Sponsors & Collaborators

  • ImmunityBio, Inc.

    collaborator INDUSTRY

  • Vadim S Koshkin

    lead OTHER

Principal Investigators

  • Vadim Koshkin, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2027-05-30
Completion
2027-05-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07217496 on ClinicalTrials.gov